The Lantern Vol. 73, No. 1, Fall 2005

• Newspaper Clippings Found on the Wall of Giuseppe Luchenzo\u27s Home When it was Raided by Police • All the Time in the World • The Man Who Would Win • Souffle Suit • A Day in the Mind • Context • Felicity / Awareness • Frivolous • Thank You Note to J.S.B. • September 17, 2005 • Eight Ways of Looking at a Highway • Dusty Glass Spreads Air Like Light • Clockwork • Rubber Band • Outside Eye or I Am? • A Mundane Mysticism • Half Carat • Things I Learned on My Trip to the Mutter Museum of Medical Oddities • Peer Editing • The Attic Bones • Yeshttps://digitalcommons.ursinus.edu/lantern/1167/thumbnail.jp

The Lantern Vol. 71, No. 2, Spring 2004

• Football Captain • Grass Blades • Identity Theft • Her Shoulders • Doing 100 • Watching the • Fifteen Lines for Five • Plague • On the Occasion of Kissing You Less Than I Used To • Decomposey • Broomhandles • Just a Minute • War of the Words • Seguidille • At the End of One\u27s Rope • The Ride and Joe • I Want Soft Curls • Broken • Stories of a Hypochondriac • The TV is in Jail & My Mom is the Wardenhttps://digitalcommons.ursinus.edu/lantern/1164/thumbnail.jp

The Lantern Vol. 72, No. 1, Fall 2004

• Jazz • Bifocal Brainfreeze • A Mug of Tea • Autumn Blend • Montana Skies • Madeleine Parenthesis • Ghosts Come Out at Night • Time • 144 Cromwell Road • Market East • Secret • Stream • What Might Have Been or What Never Was • Buried Mirth • Conversations With a Writer • Churning Through • Chum-Salmon Intentions • Cages • Lola Sang of Green Glass Landscapes • Peg\u27s Antiques • Life at 120 Decibelshttps://digitalcommons.ursinus.edu/lantern/1165/thumbnail.jp

The Lantern Vol. 73, No. 2, Spring 2006

• Of the Man • Beauty in America • Kindling • Genevieve • Bits of Copper • A Love Song to Hip Hop • From James\u27 Journal • I Want a Woman • Peregrine Rain • Resurge • Frustrations • (At Least) You Gave Me Something to Write About • The Fun of Giving Interactive History Lectures as a Summer Job • Exigence • White Water • My Summer, with Salt • The City With Two Faces • I Dig Your Cello • Life-Filled Ghost Town • Laura, On Happiness • Integration/Assimilation • Sunny Side Estates • Every Night I Shut My Eyes • New England State of Mind • Your Body\u27s Weight in Water for Your Soul, Thank You Very Much • A Story That\u27s 10 Percent Truehttps://digitalcommons.ursinus.edu/lantern/1168/thumbnail.jp

Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure : primary results of the ENABLE Trials

Objectives: The objective of this clinical trial was to evaluate the long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure. Background: Endothelin may play a role in heart failure, but short-term clinical trials with endothelin receptor antagonists have reported disappointing results. Long-term trials are lacking. Methods: In 2 identical double-blind trials, we randomly assigned 1,613 patients with New York Heart Association functional class IIIb to IV heart failure and an ejection fraction <35% to receive placebo or bosentan (target dose 125 mg twice daily) for a median of 1.5 years. The primary outcome for each trial was clinical status at 9 months (assessed by the hierarchical clinical composite); the primary outcome across the 2 trials was death from any cause or hospitalization for heart failure. Results: Bosentan did not influence clinical status at 9 months in either trial (p = 0.928 and p = 0.263). In addition, 321 patients in the placebo group and 312 patients in the bosentan group died or were hospitalized for heart failure (hazard ratio [HR]: 1.01; 95% confidence interval [CI]: 0.86 to 1.18; p = 0.90). The bosentan group experienced fluid retention within the first 2 to 4 weeks, as evidenced by increased peripheral edema, weight gain, decreases in hemoglobin, and an increased risk of hospitalization for heart failure, despite intensification of background diuretics. During follow-up, 173 patients died in the placebo group and 160 patients died in the bosentan group (HR: 0.94; 95% CI: 0.75 to 1.16). About 10% of the bosentan group showed meaningful increases in hepatic transaminases, but none had acute or chronic liver failure. Conclusions: Bosentan did not improve the clinical course or natural history of patients with severe chronic heart failure and but caused early and important fluid retention